TY  - JOUR
AU  - Ringborg, Ulrik
AU  - von Braun, Joachim
AU  - Celis, Julio
AU  - Baumann, Michael
AU  - Berns, Anton
AU  - Eggermont, Alexander
AU  - Heard, Edith
AU  - Heitor, Manuel
AU  - Chandy, Mammen
AU  - Chen, Chien-Jen
AU  - Costa, Alberto
AU  - De Lorenzo, Francesco
AU  - De Robertis, Edward M
AU  - Dubee, Frederick Charles
AU  - Ernberg, Ingemar
AU  - Gabriel, Mariya
AU  - Helland, Åslaug
AU  - Henrique, Rui
AU  - Jönsson, Bengt
AU  - Kallioniemi, Olli
AU  - Korbel, Jan
AU  - Krause, Mechthild
AU  - Lowy, Douglas R
AU  - Michielin, Olivier
AU  - Nagy, Peter
AU  - Oberst, Simon
AU  - Paglia, Vincenzo
AU  - Parker, M Iqbal
AU  - Ryan, Kevin
AU  - Sawyers, Charles L
AU  - Schüz, Joachim
AU  - Silkaitis, Katherine
AU  - Solary, Eric
AU  - Thomas, David
AU  - Turkson, Peter
AU  - Weiderpass, Elisabete
AU  - Yang, Huanming
TI  - Strategies to decrease inequalities in cancer therapeutics, care and prevention.
JO  - Molecular oncology
VL  - 18
IS  - 2
SN  - 1574-7891
CY  - Hoboken, NJ
PB  - John Wiley & Sons, Inc.
M1  - DKFZ-2023-02815
SP  - 245-279
PY  - 2024
N1  - 2024 Feb;18(2):245-279
AB  - Analyses of inequalities related to prevention and cancer therapeutics/care show disparities between countries with different economic standing, and within countries with high Gross Domestic Product. The development of basic, technological and biological research provides clinical and prevention opportunities that make their implementation into healthcare systems more complex, mainly due to the growth of Personalized/Precision Cancer Medicine (PCM). Initiatives like the US-Cancer Moonshot and the EU-Mission on Cancer and Europe´s Beating Cancer Plan are initiated to boost cancer prevention and therapeutics/care innovation and to mitigate present inequalities. The conference organised by the Pontifical Academy of Sciences in collaboration with the European Academy of Cancer Sciences discussed the inequality problem, dependent on the economic status of a country, the increasing demands for infrastructure supportive of innovative research and its implementation in healthcare and prevention programs. Establishing translational research and a coherent cancer research continuum is still a challenge. Research has to cover the entire continuum from basic to outcomes research for clinical and prevention components. Comprehensive Cancer Centres (CCCs) are of critical importance for integrating research innovations to preclinical and early clinical research, as for ensuring state-of-the-art patient care within healthcare systems. International collaborative networks between CCCs are necessary to reach the critical mass of infrastructures and patients for PCM research, and for introducing prevention modalities and new treatments effectively. Outcomes and health economics research are required to assess the cost-effectiveness of new interventions, currently a missing element in the research portfolio. Data sharing and critical mass are essential for innovative research to develop PCM. Despite advances in cancer research, cancer incidence and prevalence is growing. Making cancer research infrastructures accessible for all patients, considering the increasing inequalities, requires science policy actions incentivising research aimed at prevention and cancer therapeutics/care with an increased focus on patients´ needs and cost-effective healthcare.
KW  - Cancer therapeutics/care (Other)
KW  - cancer prevention (Other)
KW  - healthcare (Other)
KW  - inequalities (Other)
KW  - science policy (Other)
KW  - translational cancer research (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:38135904
DO  - DOI:10.1002/1878-0261.13575
UR  - https://inrepo02.dkfz.de/record/286603
ER  -